Indexed with PubMed and Science Citation Index (E) 
Users online: 4845 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Article in PDF (463 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

  In this article

 Article Access Statistics
    PDF Downloaded31    
    Comments [Add]    

Recommend this journal


 Table of Contents    
Year : 2018  |  Volume : 84  |  Issue : 4  |  Page : 445

Author's reply

Stanley Browne Laboratory, The Leprosy Mission Trust India, Leprosy Community Hospital, Shahdara, New Delhi, India

Date of Web Publication11-Jun-2018

Correspondence Address:
Utpal Sengupta
Stanley Browne Laboratory, The Leprosy Mission Trust India, Leprosy Community Hospital, Shahdara, New Delhi
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijdvl.IJDVL_343_18

Rights and Permissions

How to cite this article:
Sengupta U. Author's reply. Indian J Dermatol Venereol Leprol 2018;84:445

How to cite this URL:
Sengupta U. Author's reply. Indian J Dermatol Venereol Leprol [serial online] 2018 [cited 2019 Nov 21];84:445. Available from: http://www.ijdvl.com/text.asp?2018/84/4/445/234058


The action plan to halt transmission of Mycobacterium leprae infection, which has been described in page 3 of the review, definitely mentions the single-dose rifampicin administration to contacts of index cases which has been adopted by the Government of India as one of the procedures to curtail transmission, but has not discussed in depth its pros and cons in suitability in curtailing M. leprae transmission. However, the issue of drug resistance has been discussed and it has been cautioned in the last line under The protection of contacts of index cases from getting M. leprae infection in page 3: “Considering the above, especially when secondary rifampicin resistance is being reported from various endemic regions of leprosy whether single-dose rifampicin for chemoprophylaxis will be a wise proposition for reduction in transmission of infection will be revealed only from the future survey of contacts of index cases who will be subjected to chemoprophylaxis under the control program.”

I fully agree with the views and concern of Dr. Bhushan Kumar regarding its implementation in the National Leprosy Eradication Program. In addition to the points raised by the correspondent, it is to be mentioned that considering the average half-life of rifampicin to be 3.35 (±0.66) hours [1], the antibacterial activity will remain for too short a time! If the primary focus of infection remains in peripheral nerves, the drug will be cleared before its penetration in nerve.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

  References Top

Available on https://www.rxlist.com/rifadin-drug.htm. [Last accessed on 2018 Apr 15].  Back to cited text no. 1


Print this article  Email this article


Online since 15th March '04
Published by Wolters Kluwer - Medknow